Renal cell carcinoma

Nab-paclitaxel

Details

Key Milestones2
Call for patient/clinician input openNovember 29, 2023
Call for patient/clinician input closedJanuary 29, 2024
Call for industry input openNovember 29, 2023
Call for industry input closedJanuary 29, 2024
Submission receivedOctober 24, 2023
Review initiatedOctober 25, 2023
Expert committee meeting (initial)May 10, 2024
Draft recommendation posted for stakeholder feedbackJune 06, 2024
End of feedback periodJune 20, 2024
Final recommendation postedJuly 24, 2024
Canada's Drug Agency review report(s) postedJuly 16, 2024

Unresectable Hepatocellular Carcinoma

burosumab

Details

Key Milestones2
Call for patient/clinician input openNovember 14, 2023
Call for patient/clinician input closedJanuary 12, 2024
Clarification:

- Patient input submission received from Canadian XLH Network

Submission receivedJanuary 02, 2024
Submission acceptedJanuary 16, 2024
Review initiatedJanuary 17, 2024
Draft CADTH review report(s) provided to sponsor for commentApril 04, 2024
Deadline for sponsors commentsApril 15, 2024
CADTH review report(s) and responses to comments provided to sponsorMay 09, 2024
Expert committee meeting (initial)May 22, 2024
Draft recommendation issued to sponsorJune 04, 2024
Draft recommendation posted for stakeholder feedbackJune 13, 2024
End of feedback periodJune 27, 2024
Clarification:

- Reconsideration: minor revisions requested by drug programs

- Request for reconsideration accepted

- Reconsideration: major revisions requested by drug programs

- Request for reconsideration accepted

Expert committee meetingSeptember 25, 2024
Final recommendation issued to sponsor and drug plansOctober 10, 2024
Final recommendation postedOctober 29, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)October 25, 2024
CADTH review report(s) postedFebruary 12, 2025

Nivolumab and Ipilimumab

Details

Key Milestones2
Call for patient/clinician input openNovember 09, 2023
Call for patient/clinician input closedJanuary 08, 2024
Call for industry input openNovember 09, 2023
Call for industry input closedJanuary 08, 2024
Submission receivedOctober 24, 2023
Review initiatedOctober 25, 2023
Expert committee meeting (initial)May 10, 2024
Draft recommendation posted for stakeholder feedbackJune 06, 2024
End of feedback periodJune 20, 2024
Final recommendation postedAugust 01, 2024
Canada's Drug Agency review report(s) postedAugust 01, 2024

Pembrolizumab

Details

Key Milestones2
Call for patient/clinician input openNovember 09, 2023
Call for patient/clinician input closedJanuary 08, 2024
Call for industry input openNovember 09, 2023
Call for industry input closedJanuary 08, 2024
Submission receivedOctober 24, 2023
Review initiatedOctober 25, 2023
Expert committee meeting (initial)May 10, 2024
Final recommendation postedAugust 01, 2024
Canada's Drug Agency review report(s) postedAugust 01, 2024

cariprazine

Details

Key Milestones2
Call for patient/clinician input openNovember 08, 2023
Call for patient/clinician input closedJanuary 08, 2024
Clarification:

- Patient input submission received from Schizophrenia Society of Canada

Submission receivedDecember 20, 2023
Submission acceptedJanuary 11, 2024
Review initiatedJanuary 12, 2024
Draft CADTH review report(s) provided to sponsor for commentApril 08, 2024
Deadline for sponsors commentsApril 17, 2024
CADTH review report(s) and responses to comments provided to sponsorMay 09, 2024
Expert committee meeting (initial)May 22, 2024
Clarification:

Recommendation deferred to June 26, 2024 CDEC meeting

Draft recommendation issued to sponsorJuly 10, 2024
Draft recommendation posted for stakeholder feedbackJuly 18, 2024
End of feedback periodAugust 01, 2024
Final recommendation issued to sponsor and drug plansAugust 15, 2024
Final recommendation postedSeptember 03, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 29, 2024
CADTH review report(s) postedJanuary 16, 2025

osimertinib

Details

Key Milestones2
Call for patient/clinician input openOctober 30, 2023
Call for patient/clinician input closedDecember 22, 2023
Clarification:

- Patient input submission received from Lung Cancer Canada and the Lung Health Foundation

Submission receivedDecember 11, 2023
Submission acceptedJanuary 02, 2024
Clarification:

- Additional information has been received and the temporary suspension of the review has been lifted

Review initiatedJanuary 03, 2024
Draft CADTH review report(s) provided to sponsor for commentJune 21, 2024
Deadline for sponsors commentsJuly 03, 2024
CADTH review report(s) and responses to comments provided to sponsorAugust 01, 2024
Expert committee meeting (initial)August 14, 2024
Draft recommendation issued to sponsorAugust 26, 2024
Draft recommendation posted for stakeholder feedbackSeptember 05, 2024
End of feedback periodSeptember 19, 2024
Final recommendation issued to sponsor and drug plansOctober 03, 2024
Final recommendation postedOctober 22, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)October 18, 2024
CADTH review report(s) postedJanuary 29, 2025